SMIN:LSESmiths Group Plc Analysis
Data as of 2026-08-03 - not real-time
Latest Price
Risk Level: Medium
Executive Summary
Smiths Group plc is trading at 2,642 GBp, comfortably above its 20‑day SMA (2,575) and 50‑day SMA (2,550) while still below the 200‑day SMA (2,503), indicating a sustained bullish bias. The technical suite is supportive – the MACD histogram is positive (≈5.4) and the signal is bullish, while the RSI sits at a neutral 56, suggesting room for upside without immediate overbought pressure. Valuation metrics are mixed: a trailing P/E of 35.7 exceeds the industry average of 30.9, and a P/B of 5.15 signals premium pricing, yet the DCF‑derived fair value of ~835 GBp implies a substantial upside potential, reflected in the model’s 6.7 % upside estimate. The company delivers a modest 1.77 % dividend yield with a payout ratio of 62 %, supported by positive operating cash flow (≈£374 m) despite a sizable negative free cash flow and a debt‑to‑equity of 73 %, which raises leverage concerns. Volatility is elevated at 25.9 % over the past 30 days, but beta is low (≈0.49), tempering systematic risk. Overall, the stock sits near a key resistance around 2,715 GBp, with decreasing volume hinting at a potential short‑term pause, while the “Extreme Greed” sentiment index underscores strong market optimism.
Market Outlook
Short Term
< 1 yearKey Factors
- Bullish MACD and SMA alignment supports near‑term stability
- Price approaching resistance at 2,715 GBp may trigger a pullback
- Decreasing volume adds uncertainty to immediate moves
Medium Term
1–3 yearsKey Factors
- Forward EPS growth improves valuation (forward P/E ~23)
- Dividend yield of 1.77 % offers income while earnings recover
- Modelled upside of ~6.7 % aligns with target median price (~2,835 GBp)
Long Term
> 3 yearsKey Factors
- Diversified industrial segments provide resilient cash flows
- High debt‑to‑equity and negative free cash flow pose balance‑sheet risk
- Elevated valuation multiples may limit long‑run price appreciation
Key Metrics & Analysis
Financial Health
Technical Analysis
Valuation
Risk Assessment
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.